Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline
Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, today announced its $33.5 million Series B. The round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray.
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle HealthREDWOOD CITY, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, today announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) to discover, develop, and commercialize drug candidates that improve muscle health and body composition.
Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, announced today that it is enrolling participants into its clinical trial evaluating JUV-161, a first-in-class fusion protein that enhances muscle regeneration through its pro-myogenic, insulin-resistance modulating, and anti-inflammatory properties. JUV-161 is a muscle regenerating endocrine therapy being investigated for the treatment of Myotonic Dystrophy Type 1 (DM1) and Sarcopenia. JUV-161 received FDA Orphan Disease Drug designation for DM1 in 2024.
Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
Juvena Therapeutics, a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161. JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult muscular dystrophy.
